Jun 15,2023

Global Glucose Monitoring Market Report Analysis Report 2023: Growing Diffusion of Smart Devices and Digital Platforms Increasing Compliance and Management of Diabetes

The global glucose monitoring market is projected to grow at a double-digit CAGR, reaching $33,886.4 million by 2029, according to the publisher of a report. Factors such as increasing prevalence of diabetes, demand for less invasive devices, and growing adoption of smart devices and digital platforms are driving market growth. Major players in the market include Abbott Laboratories, Dexcom, Roche, and Medtronic, among others.

View Analyst & Ambassador Comments
Go to original news
Jun 15,2023

Nemaura Medical to Exhibit and Provide Live Product Demonstrations of Its Non-invasive Glucose Sensor at the 83rd Scientific Sessions of the American Diabetes Association June 23-26, 2023

Nemaura will showcase its non-invasive glucose sensor at the 83rd Scientific Sessions of the American Diabetes Association. The event will be held from June 23-26, 2023, providing an opportunity for the company to demonstrate its technology for personalized diabetes management.

CONFERENCES

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 16,2023

The Insulin Pens Market is Expected to Surge US$ 35.2 Billion by 2033

The global Insulin Pens Market is projected to reach US$ 35.2 billion by 2033, with a market value of US$ 16.2 billion in 2022. The market is expected to expand at a CAGR of 7.3% from 2023 to 2033. Key players are focusing on partnerships and diversification of product portfolios to meet the growing demand for innovative insulin pen technologies.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 14,2023 TOP STORY

Lark Health Announces the Results from Cost Savings Study in DPP

Lark Health announced two new research studies demonstrating the effectiveness of diabetes prevention programs (DPP) and cardiac self-efficacy (CSE). The study, published in Obesity Science and Practice and titled, "Weight Loss and Modeled Cost Savings in a Digital Diabetes Prevention Program," confirms that Lark's scalable, AI-based DPP can reduce staffing needs and shows cost savings for DPPs delivered via other modalities (e.g., in-person, hybrid). Significant cost savings was also calculated by the findings. The estimated medical cost savings for 11,976 members who achieved weight loss and participation outcomes was $12,957,073.

CLINICAL STUDY

#coaching

#dtx

View Analyst & Ambassador Comments
Go to original news
Jun 12,2023

Dexcom study shows diabetes’ impact on mental health

A Dexcom study shows that diabetes has a significant negative impact on mental health, according to 84% of respondents. Additionally, 91% believe that technology enables a balanced lifestyle while managing diabetes. Dexcom, a maker of continuous glucose monitor (CGM) technology, announced results ahead of the UK’s Diabetes Awareness Week. It included responses from 1,000 nationally representative UK respondents aged 16 years and up living with diabetes.

View Analyst & Ambassador Comments
Go to original news
Jun 12,2023

Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions

Medtronic will be participating in the American Diabetes Association's 83rd Scientific Sessions, on Jun. 23-26, 2023. During the conference, Medtronic will present new data and clinical outcomes across a broad population of patients from its newly FDA-approved MiniMed™ 780G system with Guardian™ 4 sensor — which began shipping in the U.S. earlier this month — as well as their Extended Infusion Set and InPen™ smart insulin pen.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 12,2023

Abbott changes executive team with new CFO

Abbott announces a series of personnel changes, appointing Philip Boudreau as CFO, effective September 1, 2023. Robert Funck transitions to EVP, finance, and John McCoy, Jr. becomes VP, controller. The changes mark a milestone in the company's executive team. Boudreau became Abbott’s VP, controller in 2020 and served in that role since. Funck joined Abbott in 1989 and served as a corporate officer starting in 2005. McCoy, meanwhile, has been Abbott’s VP, treasurer since 2021.

View Analyst & Ambassador Comments
Go to original news
Jun 13,2023

Medtronic begins U.S. shipments of MiniMed 780G, looks to next-gen CGM

Medtronic said it began shipping its next-generation MiniMed 780G automated insulin delivery system in the U.S. this month. Medtronic’s new artificial pancreas system offers meal detection technology. Additionally, CEO Geoff Martha offered some insights into the Diabetes unit’s product pipeline during the Goldman Sachs global healthcare conference. Medtronic’s diabetes pipeline includes a next-generation continuous glucose monitor (CGM) sensor that is half the size of the company’s present sensor. The medtech giant announced that it received FDA approval for MiniMed 780G with the Guardian 4 sensor in April.

PRODUCT

#insulin pump

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news

Digital Diabetes Fundings 2014-2022: Trends, Most Funded Companies & Active Investors

Summary

This expert-led presentation on the investments in the Digital Diabetes market segment between 2014-2022 provides an analysis of the fundings in different time periods, the top 5 most invested digital diabetes companies and use case breakdown of their solutions, and lastly the investor landscape of the digital diabetes market.

Author: Melis Ince, Senior Market Analyst and Consultant at Research2Guidance

Jun 12,2023

Simple HealthKit inks deal with Walmart to expand access to at-home tests

Simple HealthKit has inked a deal with Walmart to bring at-home diagnostic tests, including diabetes, respiratory wellness and sexual wellness labs, to the largest retailer in the world. Through the retail giant’s website, customers can purchase tests bolstered by Simple HealthKit’s end-to-end healthcare infrastructure including testing, follow-up and treatment. The digital health company’s HbA1c test identifies key markers for Type 2 diabetes. Those who receive abnormal test results will be connected with a provider at no additional cost. Patients can also opt to review results and treatment plans with their preexisting primary care provider

COLLABORATION PARTNERSHIP

#product & service

#virtual care

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES